[go: up one dir, main page]

PE20000281A1 - Inhibidores de celulas b - Google Patents

Inhibidores de celulas b

Info

Publication number
PE20000281A1
PE20000281A1 PE1999000110A PE00011099A PE20000281A1 PE 20000281 A1 PE20000281 A1 PE 20000281A1 PE 1999000110 A PE1999000110 A PE 1999000110A PE 00011099 A PE00011099 A PE 00011099A PE 20000281 A1 PE20000281 A1 PE 20000281A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
alcoxy
group
ilica
Prior art date
Application number
PE1999000110A
Other languages
English (en)
Inventor
Rainer Albert
Christoph Heusser
Elsebeth Andersen
Alexander Hagenbach
Anette Wienand
Christos Papageorgiou
Max H Schreier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802842.6A external-priority patent/GB9802842D0/en
Priority claimed from GBGB9810688.3A external-priority patent/GB9810688D0/en
Priority claimed from GBGB9826553.1A external-priority patent/GB9826553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20000281A1 publication Critical patent/PE20000281A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A AMIDAS DE FORMULA T-C(=Z)-NH-(CH2)n-W, DONDE 1) Z ES O; n ES 0; T ES UN GRUPO a; R6 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, OH, NR7R8, COOH, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C4, CHO, HETEROCICLO, ENTRE OTROS; R9 Y R10 SON ALQUILO C1-C6 SUSTITUIDO POR OH, NR7R8; W ES UN GRUPO b; X ES -CR1=, R1 ES H, F, CF3, ALQUILO C1-C4, NH2; R2 ES H, F, OH, ALCOXI C1-C4, CN, NO2, CF3, NHCO-ALQUILO C1-C4; R3 ES H, HALOGENO, CN, NO2, CF3, NH2, OH; R4 ES H, HALOGENO, CF3, ALCOXI C1-C4; R5 ES H, HALOGENO, ALCOXI C1-C4, TIOALQUILO C1-C4, CF3, NH2, ENTRE OTROS. 2)Z ES O o S; n ES 0 o 1; T ES UN GRUPO c; R11 ES H, CH3, C2H5; R12 ES H, HALOGENO, CICLOALQUILO C3-C6; R13 ES H, HALOGENO, OH, ALCOXI C1-C2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS AMIDA (4-CLORO-3-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, AMIDA (5-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO INHIBE LA PRODUCCION DE ANTICUERPOS IgM DE CELULAS B; SIN BLOQUEAR LA ACTIVIDAD DE DIHIDRO-OROTATO DESHIDROGENASA (DHODH) Y SON UTILES PARA PREVENIR O REDUCIR LAS RESPUESTAS INMUNES DE ANTICUERPOS
PE1999000110A 1998-02-10 1999-02-09 Inhibidores de celulas b PE20000281A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802842.6A GB9802842D0 (en) 1998-02-10 1998-02-10 Organic compounds
GBGB9810688.3A GB9810688D0 (en) 1998-05-19 1998-05-19 Organic compounds
GBGB9826553.1A GB9826553D0 (en) 1998-12-02 1998-12-02 Organic compounds

Publications (1)

Publication Number Publication Date
PE20000281A1 true PE20000281A1 (es) 2000-05-15

Family

ID=27269204

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000110A PE20000281A1 (es) 1998-02-10 1999-02-09 Inhibidores de celulas b

Country Status (5)

Country Link
AR (1) AR015514A1 (es)
AU (1) AU2832399A (es)
CO (1) CO4980854A1 (es)
PE (1) PE20000281A1 (es)
WO (1) WO1999041239A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012189A1 (en) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
NZ526336A (en) 2000-12-07 2004-11-26 Cv Therapeutics Inc Substituted 1, 3,5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7375232B2 (en) 2001-08-15 2008-05-20 E.I. Du Pont De Nemours And Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN102985405B (zh) * 2010-07-02 2016-07-06 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
US9499484B2 (en) * 2012-04-02 2016-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof
AP2016009156A0 (en) 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10730839B2 (en) * 2016-11-27 2020-08-04 Russell Dahl Quinolines as cytoprotective agents
CN111164075A (zh) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 用作fgfr4抑制剂的稠环衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (es) * 1969-02-26 1973-01-31
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
FR2121394A1 (fr) * 1971-01-08 1972-08-25 Anvar Procédé d'obtention de dérivés d'acides indole carboxyliques et produits préparables par ce procédé.
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands

Also Published As

Publication number Publication date
AR015514A1 (es) 2001-05-02
WO1999041239A1 (en) 1999-08-19
CO4980854A1 (es) 2000-11-27
AU2832399A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
PE20000281A1 (es) Inhibidores de celulas b
AR016307A1 (es) Imidazopirimidinas e imidazopiridinas, metodo para el tratamiento de afecciones neurologicas, y composicion farmaceutica.
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
NO981496L (no) Imidazolderivater med affinitet for <alfa> 2 reseptoraktivitet
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
DE3855144D1 (de) Verwendung von bestimmten 5-HT3-Rezeptorantagonisten zur Behandlung von Eingeweideschmerzen
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE20000564A1 (es) Antagonistas receptores y5 de neuropeptidos
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
ATE186727T1 (de) Substituierte 3-arylidinene-7-azaoxindol verbindungen und verfahren zu ihrer herstellung
AR035695A1 (es) Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
MX174596B (es) Procedimiento para la preparacion de derivados enol-eter de oxicams
AR004015A1 (es) Procedimiento para preparar compuestos de quinolina o sales farmaceuticamente aceptables de los mismos, y compuestos intermediarios
PT96070A (pt) Processo para a preparacao de derivados heterociclicos acilo aminodiol beta-amino acido
DK0812838T3 (da) Pyridoncarboxylsyrederivater substitueret med bicyclisk aminogruppe, estere og salte deraf og bicyclisk amin som mellemprodukt
DE69316392D1 (de) Azanoradamantane
GB2001309A (en) alpha -Halomethyl beta -(3-indolyl) amino acids and derivatives
ES8602712A1 (es) Un procedimiento para preparar un derivado de rodanina
ATE188695T1 (de) Indolderivate als 5-alpha-reductase-1 inhibitoren
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
HU0001727D0 (en) Novel 1-aza-2-alkyl-6-aryl-cycloalkane compounds, process for producing them and medicaments containing the same
PT911336E (pt) Derivados do acido piridonacarboxilico e intermediarios para a sua sintese
PE20001035A1 (es) Derivados de benzoxazina y benzotiazina como inhibidores de monoxido de nitrogeno sintasa
ES8201539A1 (es) Procedimiento de preparacion de nuevas ortoarilideneaminofe-netilaminas y de sus sales de adicion con acidos farmacolo- gicamente compatibles

Legal Events

Date Code Title Description
FC Refusal